Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 7/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5415125 | 0.88 | TRPV1 (0.47) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4972115 | 0.81 | BRAF (0.41) | TRPV1RAB9ANPC1LMNAMET | |
| SCHEMBL1396719 | 0.80 | TRPV1 (0.48) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4968206 | 0.74 | TRPV1 (0.60) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4974501 | 0.74 | TRPV1 (0.37) | TRPV1METEGFRPDGFRBKIT | |
| SCHEMBL4973095 | 0.73 | TRPV1 (0.49) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4979584 | 0.71 | RAB9A (0.47) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4971839 | 0.71 | RAB9A (0.45) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4975287 | 0.71 | PDPK1 (0.39) | TRPV1RAB9ANPC1METEGFR | |
| SCHEMBL4969667 | 0.71 | TRPV1 (0.48) | TRPV1RAB9ANPC1CASP3SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104161-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104161-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | MET, HGF, HDGF | TRPV1 4765/4885RAB9A 1908/4885NPC1 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.